Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: alector.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $9.00 → $2.50 | Outperform → Neutral | Mizuho |
| 12/16/2024 | $4.00 | Buy → Hold | Stifel |
| 12/4/2024 | $9.00 → $1.00 | Neutral → Underperform | BofA Securities |
| 11/29/2024 | $35.00 → $7.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $10.00 → $3.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/14/2023 | $8.00 → $15.00 | Hold → Buy | Stifel |
| 12/12/2023 | $12.00 | Buy | Deutsche Bank |
| 9/25/2023 | $4.00 | Sell | Goldman |
| 9/22/2023 | $13.00 | Overweight | Cantor Fitzgerald |
| 1/6/2023 | $24.00 → $12.00 | Buy → Neutral | BofA Securities |